New skin patch could deliver cancer medication without pain

Researchers have developed a new skin patch that could efficiently deliver medication to attack melanoma cancer cells.
The study — which will be presented at the ‘American Chemical Society Fall 2019 National Meeting’ — is an advance toward developing a vaccine to treat melanoma.
“Our patch has a unique chemical coating and mode of action that allows it to be applied and removed from the skin in just a minute while still delivering a therapeutic dose of drugs,” said Yanpu He, a graduate student who helped develop the device.
Paula T Hammond, PhD, along with her graduate students He, Celestine Hong and other colleagues at the Massachusetts Institute of Technology (MIT), designed a new pH-responsive polymer with two parts.
“The first part contains amine groups that are positively charged at the pH at which we make the microneedles, but that becomes neutral at the pH of the skin,” he explained.
“The second part contains carboxylic acid groups with no charge when the microneedles are made, but which become negatively charged when the patch is applied to the skin. So there is an overall change in charge from positive to negative,” he said.
While sticky negative-positive-negative layers are still required for layer-by-layer (LbL) film construction, the team’s patch quickly switches to repelling negative-negative-negative layers when placed on the skin. After the microneedles pierce the skin and implant the LbL drug film beneath the skin, the drug leaves the patch quickly.
Using chicken ovalbumin as a model antigen, the team vaccinated mice with their patches and compared the results with intramuscular and subcutaneous injections.
The microneedle treatment produced nine times the antibody level as compared to intramuscular injections (e.g., used for flu shots) and 160 times the antibody level compared to subcutaneous injections (e.g., used for measles vaccines). They also saw efficient immune activation in surgical samples of human skin.
“Our patch technology could be used to deliver vaccines to combat different infectious diseases,” Hammond said. “But we are excited by the possibility that the patch is another tool in the oncologists’ arsenal against cancer, specifically melanoma.”
To make a melanoma vaccine, the researchers developed an antigen that includes a marker frequently overexpressed by melanoma cells, as well as an adjuvant, which creates a generalised danger signal for the immune system and boosts its response. Then, they tested different LbL microneedle film arrangements of antigen and adjuvant in immune cells derived from mice.
From these experiments, the researchers identified the optimal LbL microneedle structure that appears to activate immune cells directly accessible in the skin. In living mice, these cells could, in turn, migrate to the lymphatic system and recruit other immune cells to attack the melanoma tumour. The researchers now plan to test the patches on melanoma tumours in mice.
“We are using low-cost chemistry and a simple fabrication scheme to transform vaccination,” Hammond said. “Ultimately, we want to get a device approved and on the market,” he added. (ANI)